Protocol for a multicentred randomised controlled trial investigating the use of personalised golimumab dosing tailored to inflammatory load in ulcerative colitis: the GOAL-ARC study (GLM dose Optimisation to Adequate Levels to Achieve Response in Colitis) led by the INITIAtive group (NCT 0268772)

Journal article published in 2018 by Juliette Sheridan, Carol Ann Coe, Peter Doran , Laurence Egan, Garret Cullen, David Kevans, Jan Leyden, Marie Galligan, Aoibhlinn O’Toole, Jane McCarthy, Glen Doherty

This paper is made freely available by the publisher.

Full text: Download

Preprint: archiving allowed

Upload

Postprint: archiving allowed

Upload

Published version: archiving allowed

Upload

Policy details

Data provided by